London, UK, 11 Dec 2006 – Cancer Research Technology Ltd (CRT), the oncology-focused development and commercialisation company and The Institute of Cancer Research (The Institute), Europe’s leading cancer research centre, today announce that they are to receive a milestone payment from Vernalis Plc (Vernalis) following the selection of a second preclinical development candidate by Vernalis’ partner Novartis in their Hsp90 drug discovery programme.
